Is management with lamivudine always the appropriate choice for HBV patients with onco-hematologic diseases?

Ann Hematol. 2009 Mar;88(3):283-4. doi: 10.1007/s00277-008-0609-2. Epub 2008 Sep 20.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Choice Behavior*
  • Disease Management
  • Follow-Up Studies
  • Hematologic Diseases / blood
  • Hematologic Diseases / complications
  • Hematologic Diseases / drug therapy*
  • Hepatitis B, Chronic / blood
  • Hepatitis B, Chronic / complications
  • Hepatitis B, Chronic / drug therapy*
  • Humans
  • Lamivudine / therapeutic use*

Substances

  • Lamivudine